DOCSLIB.ORG

Decision Summary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Decision Summary 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY A. 510(k) Number: K160447 B. Purpose for Submission: New Device C. Measurand: Fecal calprotectin D. Type of Test: Quantitative, ELISA E. Applicant: Eurospital S.p.A. F. Proprietary and Established Names: Calprest®NG G. Regulatory Information: 1. Regulation section: 21 CFR§866.5180 – Fecal calprotectin immunological test system 2. Classification: Class II 3. Product code: NXO, Calprotectin, Fecal 4. Panel: Immunology (82) 1 H. Intended Use: 1. Intended use(s): Calprest®NG is a quantitative ELISA for detecting concentration of fecal calprotectin, which can be used as an in vitro diagnostic to aid in the diagnosis of Inflammatory Bowel Diseases (IBD), specifically Crohn’s disease and ulcerative colitis, and to differentiate IBD from Irritable Bowel Syndrome (IBS) in conjunction with other clinical and laboratory findings. 2. Indication(s) for use: Same as Intended Use 3. Special conditions for use statement(s): Prescription use only 4. Special instrument requirements: Microtiter plate reader (450 nm filter) I. Device Description: The Calprest®NG kit contains the following materials: • Microtiter plate coated with rabbit anti-calprotectin antibodies (12 strips, 8 wells/strip) • Horse-radish peroxidase (HRP)-labeled mouse anti-calprotectin antibody (1 x 15 mL) • Substrate (1 x 15 mL) • Stop solution (1 x 15 mL, 0.5M H2SO4) • 20x Washing solution (1 x 50 mL) • 10x Diluent solution (1 x 20 mL) • 2.5x Extraction solution (2 x 50 mL) • Calibrators (6 x 1.5 mL, 6 vials containing 1.5 mL/vial calprotectin solution at concentration of 0, 2.5, 12.5, 25, 50, 150 ng/mL) • Control 1 (low) (1 x 1.5 mL) • Control 2 (high) (1 x 1.5 mL) J. Substantial Equivalence Information: 1. Predicate device name: Calprest® 2. Predicate 510(k) number: 2 K130945 3. Comparison with predicate: Similarities Item Device Predicate Calprest®NG Calprest® Intended to aid in the diagnosis of Same Use/Indication for Use Inflammatory Bowel Diseases (IBD), specifically Crohn’s disease and ulcerative colitis, and to differentiate IBD from Irritable Bowel Syndrome (IBS) in conjunction with other clinical and laboratory findings Analyte Calprotectin Same Assay format Quantitative Same Method Colorimetric ELISA Same Sample type Fecal Same Specimen Requirement 1.0–5.0 g stool Same Stability Washing buffer: 20–25°C for 30 days Same (Working solution) Extraction buffer: 2–8°C for 3 months Dilution buffer: 2–8°C for 30 days Stability Conjugate: 2–8°C for 30 days Same (Open vial reagents) Substrate: 2–8°C for 90 days Calibrators: 2–8°C for 30 days Controls: 2–8°C for 30 days Sample storage Stored at 2–8°C for up to 4 days Same before testing. If not tested immediately, freeze stored samples at -20°C. Differences Item Device Predicate Calprest®NG Calprest® OD reading 450 nm 405 nm Detection Antibody HRP-labeled mouse anti- Alkaline-phosphatase- calprotectin labeled rabbit anti- calprotectin Substrate TMB pNPP Stop solution H2SO4 (0.5M) None Sample dilution 1:20,000 1:2500 Control 2 controls 2 controls Control 1: 10–20 ng/mL Control 1: 20–40 ng/mL Control 2: 30–70 ng/mL Control 2: 40–85 ng/mL Calibrators 6 levels: 6 levels: 3 Differences Item Device Predicate Calprest®NG Calprest® 0, 2.5, 12.5, 25, 50, 150 6.25, 12.5, 25, 50, 100, ng/mL 200 ng/mL Conversion factor 20 2.5 Reportable range 27.1–3000 mg/kg 15.6–500 mg/kg Results interpretation Normal: 27.1– <50 mg/kg Normal: <15.6–50 mg/kg Borderline: 50–120 mg/kg Borderline: 50–120 mg/kg Abnormal: >120 mg/kg Abnormal: >120 mg/kg ELISA Procedure : Sample incubation 60 min 45 min Conjugate incubation 30 min 45 min Substrate incubation 15 min 30 min K. Standard/Guidance Document Referenced (if applicable): • CLSI EP5-A3, Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline—Third Edition • CLSI EP6-A, Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline • CLSI EP7-A2, Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition • CLSI EP17-A2, Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline—Second Edition • Guidance for Industry and FDA Staff–Class II Special Controls Guidance Document: Fecal Calprotectin Immunological Test Systems L. Test Principle: Calprest®NG is a colorimetric enzyme-linked immunosorbent assay (ELISA). The test is performed on stool samples collected without preservatives. An extract is prepared by combining the stool sample with extraction buffer and mixing for 30 minutes followed by centrifugation. The assay uses a polyclonal rabbit antibody against calprotectin as the capture antibody. Calprotectin present in the diluted stool extract sample is bound by the antibody adsorbed onto the surface of the microtiter plate. HRP-conjugated antibodies bind to the captured calprotectin. The enzyme catalyzes the conversion of the substrate (TMB) to a colored product and the optical density (OD) at 450 nm of the sample is read on an ELISA plate reader. The intensity of the color is proportional to the amount of conjugate bound, and thus to the amount of captured calprotectin. The concentration of calprotectin in the extracted sample is interpreted from a standard curve generated from the six calibrators and converted to mg of calprotectin per kg of stool using a conversion factor supplied in the package insert. M. Performance Characteristics: 4 1. Analytical performance: All results presented below were within the sponsor’s pre- determined acceptance criteria for each study. a. Precision/Reproducibility: Precision: The precision of the Calprest®NG assay was evaluated by extracting seven stool samples containing various concentration of calprotectin. Each extracted sample was tested in duplicate, two runs per day for 10 days by three different operators using one lot of reagent (total of 120 replicates per sample). The results are summarized in the table below Between- Between- Between- Total Within-Run Mean Run Day Operator (mg/kg) CV CV CV CV CV SD SD SD SD SD (%) (%) (%) (%) (%) 1 42.60 1.28 3.0 4.30 10.1 0.00 0.0 0.55 1.3 4.52 10.6 2 170.88 3.40 2.0 6.77 4.0 5.51 3.2 0.80 0.5 9.40 5.5 3 248.74 6.44 2.6 11.98 4.8 12.21 4.9 0.00 0.0 18.28 7.3 4 741.60 17.38 2.3 43.12 5.8 55.37 7.5 0.00 0.0 72.30 9.7 5 1006.17 41.69 4.1 39.67 3.9 55.80 5.5 28.24 2.8 84.98 8.4 6 1193.10 52.91 4.4 73.33 6.1 118.78 10.0 60.32 5.1 161.01 13.5 7 2267.29 223.08 9.8 83.22 3.7 155.52 6.9 58.33 2.6 290.31 12.8 Reproducibility: The lot-to-lot reproducibility was done by extracting four stool samples with calprotectin concentrations of 64.7, 259.2, 778.2, and 2005.2 mg/kg. Each extracted sample was tested in replicates of five using three different lots of the reagents. Mean and %CV for each sample were calculated and %CV values for between-lot reproducibility were 3.1%–7.3% for all samples. The site-to-site reproducibility was evaluated by testing a total of eight stool samples at three sites. The samples were run in replicates of five per day for five days at each site, and a total of 75 data points were generated for each sample. Data were analyzed for within-run, between-run, within-site, between site and total reproducibility. The results are summarized in the table below: Within-Run Between- Within-Site Between- Total Mean Day Site (mg/kg) SD CV SD CV SD CV SD CV SD CV (%) (%) (%) (%) (%) 1 36.54 3.69 10.1 3.54 9.7 5.11 14.0 0.00 0.0 5.11 14.0 2 62.08 4.19 6.8 3.78 6.1 5.64 9.1 6.60 10.6 8.68 14.0 3 356.84 12.00 3.4 27.57 7.7 30.07 8.4 42.34 11.9 51.93 14.6 4 433.80 13.43 3.1 62.56 14.4 63.99 14.8 8.47 2.0 64.55 14.9 5 682.76 35.88 5.3 34.21 5.0 49.57 7.3 61.45 9.0 78.95 11.6 6 1180.64 71.08 6.0 139.04 11.8 156.16 13.2 0.00 0.0 156.16 13.2 7 1629.44 96.29 5.9 191.96 11.8 214.76 13.2 73.04 4.5 226.84 13.9 8 2152.20 173.58 8.1 254.59 11.8 308.13 14.3 50.20 2.3 312.19 14.5 5 The extraction reproducibility was evaluated by using four stool samples with calprotectin concentrations of 29.6, 52.7, 227.0, and 1973.3 mg/kg. Each stool sample was extracted 10 times and each stool extract was tested in duplicate. The %CVs for these four stool samples are 14.6%, 11.1%, 6.8%, and 5.9%, respectively. b. Linearity/assay reportable range: Linearity: The linearity of Calprest®NG was evaluated according to the CLSI guideline EP6-A. Four sample dilution series each with nine dilution levels were prepared by serially diluting the high concentration stool extract sample pools with the low concentration stool extract sample pools.
Load more

Recommended publications
  • 329 Fecal Calprotectin Testing
    Medical Policy Fecal Calprotectin Testing Table of Contents • Policy: Commercial • Coding Information • Information Pertaining to All Policies • Policy: Medicare • Description • References • Authorization Information • Policy History Policy Number: 329 BCBSA Reference Number: 2.04.69 NCD/LCD: N/A Related Policies Fecal Analysis in the Diagnosis of Intestinal Dysbiosis, #556 Policy Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members Fecal calprotectin testing may be considered MEDICALLY NECESSARY for the evaluation of patients when the differential diagnosis is inflammatory bowel disease or noninflammatory bowel disease (including irritable bowel syndrome) for whom endoscopy with biopsy is being considered. Fecal calprotectin testing is considered INVESTIGATIONAL in the management of bowel disease, including the management of active inflammatory bowel disease and surveillance for relapse of disease in remission. Prior Authorization Information Inpatient • For services described in this policy, precertification/preauthorization IS REQUIRED for all products if the procedure is performed inpatient. Outpatient • For services described in this policy, see below for products where prior authorization might be required if the procedure is performed outpatient. Outpatient Commercial Managed Care (HMO and POS) Prior authorization is not required. Commercial PPO and Indemnity Prior authorization is not required. Medicare HMO BlueSM Prior authorization is not required. Medicare PPO BlueSM Prior authorization is not required. 1 CPT Codes / HCPCS Codes / ICD Codes Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.
    [Show full text]
  • Fecal Calprotectin Testing &
    FECAL CALPROTECTIN TESTING & IBD Get the inside scoop from your poop! If you have inflammatory bowel disease (IBD), you know that inflammation in your gastrointestinal tract can cause flares. When flares strike, you might experience painful cramps, diarrhea, bleeding, and fever. But how do you know if these symptoms are from a flare or some other cause? fCal is useful in patients with inactive ulcerative colitis and Crohn’s disease, as it can help predict relapse and allow early treatment. The clue is in your poo… Benefits of Fecal Calprotectin (fCal) testing Non-invasive fCal testing requires no bowel preparation. Samples can be collected in the privacy of your home. You may still need to have a colonoscopy or biopsy. Identifies relapse or flares It’s important to know whether your symptoms are due to IBD or some other cause, so that your doctor can manage your symptoms appropriately. Large amounts of fCal in your stool mean you are likely experiencing IBD relapse. Low to normal levels usually mean your symptoms are due to something else, like irritable bowel syndrome. Monitors response to ulcerative colitis and Crohn’s disease treatment fCal levels may also be useful in monitoring disease activity and how well you are responding to your treatment. It may even help your doctor predict relapse if your fCal levels are high. When? There are no clear guidelines on how often you should take the fCal test, and fCal levels may vary for each person. It may be useful to monitor your level when your IBD is in remission.
    [Show full text]
  • Calprotectin – Scientific Literature R-Biopharm – for Reliable Diagnostics
    R-Biopharm – for reliable diagnostics Calprotectin – scientific literature R-Biopharm – for reliable diagnostics Content 1. Highlights ............................................................................................................3 2. Benefits of calprotectin management ..................................................................4 3. Calprotectin as a marker for the diagnosis of IBD ................................................5 3.1. Adult patients ......................................................................................................5 3.2. Pediatric patients ................................................................................................5 3.3. Cost-effectiveness of calprotectin measurements for suspected inflammatory bowel disease ................................................................................6 3.4. Diagnostic algorithm for suspected inflammatory bowel disease .........................6 4. Calprotectin as a surrogate marker for disease activity in IBD ������������������������������7 5. Calprotectin as a surrogate marker for mucosal healing in IBD ...........................8 6. Calprotectin as a predictive marker for relapse in IBD �����������������������������������������9 7. Calprotectin as a predictive marker for post-operative relapse in Crohn’s disease .............................................................................................10 8. Calprotectin as an aid in the decision to stop an IBD drug ................................. 11 9. Calprotectin and
    [Show full text]
  • Calprotectin and Calgranulin C Serum Levels in Bacterial Sepsis
    Diagnostic Microbiology and Infectious Disease 93 (2019) 219–226 Contents lists available at ScienceDirect Diagnostic Microbiology and Infectious Disease journal homepage: www.elsevier.com/locate/diagmicrobio ☆ Calprotectin and calgranulin C serum levels in bacterial sepsis Eva Bartáková a,MarekŠtefan a,Alžběta Stráníková a, Lenka Pospíšilová b, Simona Arientová a,Ondřej Beran a, Marie Blahutová b, Jan Máca a,c,MichalHoluba,⁎ a Department of Infectious Diseases, First Faculty of Medicine, Charles University and Military University Hospital Prague, U Vojenské nemocnice 1200, 169 02 Praha 6, Czech Republic b Department of Clinical Biochemistry, Military University Hospital Prague, U Vojenské nemocnice 1200, 169 02 Praha 6, Czech Republic c Department of Anesthesiology and Intensive Care Medicine, University Hospital of Ostrava, 17. listopadu 1790/5, 708 52 Ostrava-Poruba, Czech Republic article info abstract Article history: The aim of this study was to evaluate the serum levels of calprotectin and calgranulin C and routine biomarkers in Received 26 March 2018 patients with bacterial sepsis (BS). The initial serum concentrations of calprotectin and calgranulin C were signif- Received in revised form 2 October 2018 icantly higher in patients with BS (n = 66) than in those with viral infections (n = 24) and the healthy controls Accepted 10 October 2018 (n = 26); the level of calprotectin was found to be the best predictor of BS, followed by the neutrophil- Available online 17 October 2018 lymphocyte count ratio (NLCR) and the level of procalcitonin (PCT). The white blood cell (WBC) count and the NLCR rapidly returned to normal levels, whereas PCT levels normalized later and the increased levels of Keywords: Sepsis calprotectin, calgranulin C, and C-reactive protein persisted until the end of follow-up.
    [Show full text]
  • Calprotectin-Mediated Zinc Chelation Inhibits Pseudomonas Aeruginosa Protease Activity in Cystic Fibrosis Sputum
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.25.432981; this version posted February 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Calprotectin-mediated zinc chelation inhibits Pseudomonas aeruginosa protease activity in cystic fibrosis sputum Danielle M. Vermilyeaa, Alex W. Crockera, Alex H. Giffordb,c, and Deborah A. Hogana,# a Geisel School of Medicine at Dartmouth, Hanover, New Hampshire b Pulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire c The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, New Hampshire Running title: Calprotectin inhibits P. aeruginosa proteases # Address correspondence to: Department of Microbiology and Immunology Geisel School of Medicine at Dartmouth Rm 208 Vail Building Hanover, NH 03755 E-mail: [email protected] Tel: (603) 650-1252 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.02.25.432981; this version posted February 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 Abstract 2 Pseudomonas aeruginosa induces pathways indicative of low zinc availability in the cystic 3 fibrosis (CF) lung environment. To learn more about P. aeruginosa zinc access in CF, we grew 4 P. aeruginosa strain PAO1 directly in expectorated CF sputum.
    [Show full text]
  • The Role of Calprotectin (S100A8/A9) in the Pathogenesis of Glomerulonephritis and ANCA-Associated Vasculitis Ruth Jennifer Pepp
    The role of Calprotectin (S100A8/A9) in the pathogenesis of glomerulonephritis and ANCA-associated vasculitis Ruth Jennifer Pepper UCL Thesis submitted for the degree of Doctor of Philosophy 1 Declaration of originality I, Ruth Pepper, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicted in the thesis. 2 Abstract Glomerulonephritis is a common cause of end-stage renal failure and a feature of ANCA- associated vasculitis (AAV). AAV is an example of a small vessel vasculitis, characterised by inflammation of the endothelium and glomeruli in which the interaction between leukocytes and endothelial cells play a crucial role. Macrophages have been demonstrated to have a critical role during the initiation and progression of glomerulonephritis, with the persistence of macrophages in the renal biopsy being associated with a poorer outlook. Calprotectin (also termed S100A8/A9, mrp8/14), is a complex of 2 small calcium binding proteins that is abundantly expressed in neutrophils and monocytes as well as early infiltrating macrophages and is a known ligand of Toll-like receptor 4 (TLR4) and the receptor for advanced glycation end-products (RAGE). There is growing evidence in animal models and in patients with autoimmune diseases, of calprotectin being involved in the inflammatory response, as well as being a marker of activation of innate immunity. I have initially characterised the presence of calprotectin-positive cells in the renal biopsy of patients with focal and crescentic AAV glomerulonephritis, therefore linking the presence of these cells with renal outcome. Patients with active AAV have elevated serum calprotectin levels, as well as significant expression on neutrophils and monocytes, which although decrease during remission, does not normalise.
    [Show full text]
  • Calprotectin: an Ignored Biomarker of Neutrophilia in Pediatric Respiratory Diseases
    children Review Calprotectin: An Ignored Biomarker of Neutrophilia in Pediatric Respiratory Diseases Grigorios Chatziparasidis 1 and Ahmad Kantar 2,* 1 Primary Cilia Dyskinesia Unit, School of Medicine, University of Thessaly, 41110 Thessaly, Greece; [email protected] 2 Pediatric Asthma and Cough Centre, Instituti Ospedalieri Bergamaschi, University and Research Hospitals, 24046 Bergamo, Italy * Correspondence: [email protected] Abstract: Calprotectin (CP) is a non-covalent heterodimer formed by the subunits S100A8 (A8) and S100A9 (A9). When neutrophils become activated, undergo disruption, or die, this abundant cytosolic neutrophil protein is released. By fervently chelating trace metal ions that are essential for bacterial development, CP plays an important role in human innate immunity. It also serves as an alarmin by controlling the inflammatory response after it is released. Extracellular concentrations of CP increase in response to infection and inflammation, and are used as a biomarker of neutrophil activation in a variety of inflammatory diseases. Although it has been almost 40 years since CP was discovered, its use in daily pediatric practice is still limited. Current evidence suggests that CP could be used as a biomarker in a variety of pediatric respiratory diseases, and could become a valuable key factor in promoting diagnostic and therapeutic capacity. The aim of this study is to re-introduce CP to the medical community and to emphasize its potential role with the hope of integrating it as a useful adjunct, in the practice of pediatric respiratory medicine. Citation: Chatziparasidis, G.; Kantar, Keywords: calprotectin; S100A8/A9; children; lung A. Calprotectin: An Ignored Biomarker of Neutrophilia in Pediatric Respiratory Diseases. Children 2021, 8, 428.
    [Show full text]
  • Calprotectin, Stool
    Test Summary Calprotectin, Stool be used as 1 of the initial tests in patients with suspected IBD; Test Code: 16796 levels can help avoid unnecessary colonoscopy, as normal levels are not typically associated with active IBD.2 Conversely, Specimen Requirements: 1 g frozen stool; 0.3 g levels above normal are consistent with organic diseases such minimum as IBD and colorectal cancer, and warrant consideration of colonoscopy.2,4 CPT Code*: 83993 Calprotectin testing can also be used to monitor response to IBD treatment, since lower concentrations correlate with less severe disease and better response to treatment.5 CLINICAL USE The correlation, however, is higher in patients with colonic • Diagnose inflammatory bowel disease (IBD) than ileal disease activity.6,7 Failure of calprotectin level to normalize with treatment is considered an indication for • Differentiate IBD from irritable bowel syndrome (IBS) further endoscopic evaluation, regardless of symptoms.8 • Monitor patients with IBD for treatment response and Among IBD patients who are in remission, calprotectin helps relapse predict those who will experience a relapse. Gisbert et al CLINICAL BACKGROUND showed that an elevated calprotectin concentration predicted Inflammatory bowel disease (IBD) is characterized by chronic, relapse during the next 12 months with a sensitivity of 69% relapsing inflammation of the gastrointestinal (GI) tract lining. and a specificity of 75%.9 Costa et al showed that Crohn The 2 primary forms of IBD are Crohn disease and ulcerative disease patients in remission had a 2-fold, and ulcerative colitis, which share clinical symptoms such as abdominal colitis patients a 14-fold, increased risk of relapse when the pain, dyspepsia, and diarrhea that can be profuse and bloody.1 stool calprotectin concentration was elevated.10 Another Abdominal pain, dyspepsia, and diarrhea (non-bloody) are study showed that Crohn disease patients with an elevated also seen in patients with IBS.
    [Show full text]
  • Fecal Calprotectin Testing
    UnitedHealthcare® Commercial Medical Policy Fecal Calprotectin Testing Policy Number: 2021T0434R Effective Date: June 1, 2021 Instructions for Use Table of Contents Page Community Plan Policy Coverage Rationale ........................................................................... 1 • Fecal Calprotectin Testing Applicable Codes .............................................................................. 1 Description of Services ..................................................................... 3 Clinical Evidence ............................................................................... 4 U.S. Food and Drug Administration ................................................ 9 References ......................................................................................... 9 Policy History/Revision Information..............................................11 Instructions for Use .........................................................................11 Coverage Rationale Fecal measurement of calprotectin is proven and medically necessary for establishing the diagnosis or for management of the following: • Crohn’s Disease • Ulcerative Colitis Due to insufficient evidence of efficacy, fecal measurement of calprotectin is unproven and not medically necessary for establishing the diagnosis or for management of any other condition. Applicable Codes The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that
    [Show full text]
  • The Combination of Fecal Calprotectin with ESR, CRP and Albumin Discriminates More Accurately Children with Crohn's Disease
    Advances in Medical Sciences 64 (2019) 9–14 Contents lists available at ScienceDirect Advances in Medical Sciences journal homepage: www.elsevier.com/locate/advms Original research article The combination of fecal calprotectin with ESR, CRP and albumin T discriminates more accurately children with Crohn’s disease ⁎ Urszula Daniluka, , Jaroslaw Danilukb, Milena Krasnodebskaa, Joanna Maria Lotowskac, Maria Elzbieta Sobaniec-Lotowskac, Dariusz Marek Lebensztejna a Department of Pediatrics, Gastroenterology and Allergology, Medical University of Bialystok, Bialystok, Poland b Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland c Department of Medical Pathomorphology, Medical University of Bialystok, Bialystok, Poland ARTICLE INFO ABSTRACT Keywords: Purpose: Increased fecal calprotectin is a sensitive marker of various types of intestinal inflammation. We in- Calprotectin vestigated correlations between high fecal calprotectin concentration and serum inflammatory markers in Intestinal infection children with different intestinal diseases with diarrhea with/without blood and/or abdominal pain, totest Food protein induced proctocolitis whether the combination of these markers can differentiate potential patients with inflammatory bowel disease. Crohn’s disease Materials/methods: The study included 128 children with high fecal calprotectin concentration (> 150ug/g) and Ulcerative colitis symptoms suggesting bowel disorders, hospitalized in the years 2013– 2015. Twenty-six (20%) patients were diagnosed with Crohn’s disease, 55 (43%) with ulcerative colitis, 32 (25%) with intestinal infection and 15 (12%) with food protein induced proctocolitis. Results: Significantly increased inflammatory markers were detected in children with inflammatory boweldis- ease, with a correlation between calprotectin and erythrocyte sedimentation rate – ESR (R = 0.53), mean cor- puscular volume – MCV (R=-0.64), red blood cell distribution width (R = 0.56), albumin (R = −0.52), he- moglobin (R = −0.53) only in Crohn’s disease patients.
    [Show full text]
  • A New Rapid Quantitative Test for Fecal Calprotectin Predicts
    ORIGINAL ARTICLE A New Rapid Quantitative Test for Fecal Calprotectin Predicts Endoscopic Activity in Ulcerative Colitis Triana Lobatón Ortega, MD, Francisco Rodríguez-Moranta, MD, PhD, Alicia Lopez García, MD, Elena Sánchez Pastor, RN, Lorena Rodríguez-Alonso, MD, and Jordi Guardiola Capón, MD Background: Fecal calprotectin (FC) determined by the enzyme-linked immunosorbent assay (ELISA) test has been proposed as a promising biomarker of endoscopic activity in ulcerative colitis (UC). However, data on its accuracy in predicting endoscopic activity is scarce. Besides, FC determined by the quantitative-point-of-care test (FC-QPOCT) that provides rapid and individual results could optimize its use in clinical practice. The aims of our study were to evaluate the ability of FC to predict endoscopic activity according to the Mayo score in patients with UC when determined by FC-QPOCT and to compare it with the ELISA test (FC-ELISA). Methods: FC was determined simultaneously by FC-ELISA and FC-QPOCT in patients with UC undergoing colonoscopy. Clinical disease activity and endoscopy were assessed according to the Mayo score. Blood tests were taken to analyze serological biomarkers. Results: A total of 146 colonoscopies were performed on 123 patients with UC. FC-QPOCT correlated more closely with the Mayo endoscopic subscore (Spearman’s correlation coefficient rank r ¼ 0.727, P , 0.001) than clinical activity (r ¼ 0.636, P , 0.001), platelets (r ¼ 0.381, P , 0.001), leucocytes (r ¼ 0.300, P , 0.001), and C-reactive protein (r ¼ 0.291, P ¼ 0.002). The prediction of “endoscopic remission” (Mayo endoscopic subscore #1) with FC-QPOCT (280 mg/g) and FC-ELISA (250 mg/g) presented an area under the curve of 0.906 and 0.924, respectively.
    [Show full text]
  • Plasma-Calprotectin As an Indicator for Immediate Need of Intensive Care Treatment in Suspected Sepsis
    Plasma-Calprotectin as an Indicator for Immediate Need of Intensive Care Treatment in Suspected Sepsis Asa Emilia Parke ( [email protected] ) Karolinska Institute Department of Medicine: Karolinska Institutet Institutionen for medicin Huddinge https://orcid.org/0000-0002-2133-5323 Christian Unge KI MedH: Karolinska Institutet Institutionen for medicin Huddinge David Yu Karolinska Institute Department of Laboratory Medicine: Karolinska institutet Institutionen for laboratoriemedicin Jonas Sunden-Cullberg Karolinska Institute Department of Medicine: Karolinska Institutet Institutionen for medicin Huddinge Kristoffer Stralin Karolinska Institute Department of Medicine: Karolinska Institutet Institutionen for medicin Huddinge Research Keywords: P-calprotectin, predictor, sepsis alert, intensive care, SOFA Posted Date: March 1st, 2021 DOI: https://doi.org/10.21203/rs.3.rs-213752/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/19 Abstract Introduction: Decisions regarding need of transfer to intensive care of patients with sepsis in the emergency department is challenging. We hypothesised that the new biomarker plasma-calprotectin could be used to help select patients who need intensive care, since it already has shown to be a promising tool in the intensive care unit. Methods: This prospective study was performed on consecutive sepsis alert patients. The alert summons a multidisciplinary team of physicians from the emergency department, the Department of Infectious Diseases, and the intensive care unit, who evaluate patients for possible infection and decide where to transfer the patient. Blood sampling was performed on consecutive sepsis alert patients. C-reactive protein, procalcitonin, neutrophils, and lymphocytes were routinely analysed, p-calprotectin was analysed from frozen plasma samples using a specic turbidimetric assay.
    [Show full text]